| CAS ID: | 88040-23-7 |
| Molecular Formula: | C19H24N6O5S2 |
| Molecular Weight: | 480.6 g/mol |
| Monoisotopic Mass: | 480.125 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | BMY-28142 | MAXIPIME | Cefepime hydrochloride (arginine formulation) | BMY-28142 2HCL.H20 | CEFEPIME | CEFEPIME HYDROCHLORIDE |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1 | See All |
| InChI Key: | HVFLCNVBZFFHBT-ZKDACBOMSA-N | |
| Smiles: | CO\N=C(/C(=O)N[C@H]1[C@H]2SCC(=C(N2C1=O)C(=O)[O-])C[N+]3(C)CCCC3)\c4csc(N)n4 | See All |
| Molfile: | Download |
Reference Record 1
| PubMed ID | 27132188 | Target ID | |
| Uniprot ID | Name | ||
| Model | Fibrosis Disease | Cystic fibrosis | |
| Process I | |||
| Process II | |||
| Process III | |||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT01667094 | Disease | Cystic fibrosis |
| Phase | Phase 4 | Status | Active, not recruiting |
| First Received | August 17, 2012 | Last Verified | April 20, 2017 |
| Sponsor | The Alfred | ||